Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05276063 · ClinicalTrials.gov registry record · Phase 2
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
A Phase 2 study of Eye Diseases and Thyroid Eye Disease, sponsored by Sling Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 20
- Study locations
NCT05276063 is a Phase 2 study of Eye Diseases and Thyroid Eye Disease that is active but no longer recruiting, run by Sling Therapeutics. The registered enrollment target is 90 participants, below the 741,299-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT05276063, a Phase 2 study of Eye Diseases and Thyroid Eye Disease, is active but no longer recruiting, sponsored by Sling Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 20
- Study locations
Study Summary
The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Linsitinib
Study Locations (20)
California
- Thrive Health Research - Beverly Hills
- UC San Diego Health - La Jolla
- UCLA - Los Angeles
- Byers Eye Institute - Stanford University - Palo Alto
Florida
- Bascom Palmer Eye Institute - Miami
- Center for Excellence in Eye Care - Miami
- Sarasota Retina Institute - Sarasota
Michigan
- Kellogg Eye Center - Ann Arbor
- Kahana Oculoplastic & Orbital Surgery - Livonia
Illinois
- Chicago Oculofacial Plastic Surgery - Chicago
Iowa
- Wolfe Eye Clinic - West Des Moines
Massachusetts
- Mass Eye and Ear - Boston
Missouri
- Washington University in St. Louis/Barnes Jewish Hospital - Creve Coeur
New York
- Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05276063
The ClinicalTrials.gov registry entry for NCT05276063 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 741,299-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower). The listed sponsor is Sling Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Eye Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05276063 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT05276063 about?
NCT05276063 is a clinical study titled "A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)". The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).
What is the current status of trial NCT05276063?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2022-07-01. Estimated completion is 2026-09.
What conditions does trial NCT05276063 study?
This clinical trial studies the following conditions: Eye Diseases, Thyroid Eye Disease, Endocrine System Diseases, Graves Ophthalmopathy, Thyroid Diseases.
What interventions are being tested in trial NCT05276063?
The interventions under investigation include: Placebo (DRUG), Linsitinib (DRUG).
Who is sponsoring clinical trial NCT05276063?
This trial is sponsored by Sling Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05276063 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Iowa, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eye Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
RECRUITING · Phase 2
-
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
COMPLETED · Phase 2
-
Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
COMPLETED · Phase 2
-
Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.